VBIO: the cash flow

MyFinsight

Valion Bio, Inc. (VBIO)

Cash Flow	2026-03-31
Net loss from continuing operations	-6,225
Stock-based compensation	208
Depreciation	4
Amortization of debt discount and debt issuance costs	445
Non-cash interest expense	203
Change in fair value of derivative liability	33
Amortization of right-of-use asset	177
Prepaid expenses and other current assets	341
Inventory	750
Other assets	86
Accounts payable	365
Accrued expenses	1,114
Lease liabilities	-128
Net cash used in operating activities - continuing operations	-5,047
Net cash provided by (used in) operating activities - discontinued operations	36
Net cash used in operating activities	-5,011
Acquisition of property and equipment	7
Acquisition of licensed technology	0
Net cash used in investing activities	-7
Proceeds from warrant exercises	0
Offering costs in advance of sale of common stock	44
Net cash (used in) provided by financing activities	-44
Net decrease in cash and cash equivalents	-5,062
Beginning of period	12,645
End of period	7,583
Less cash and cash equivalents included in discontinued operations	0
Cash and cash equivalents included in continuing operations	7,583

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.